{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:31:27Z","timestamp":1793496687859,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejim.2023.11.012","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T09:43:12Z","timestamp":1700905392000},"page":"28-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"special_numbering":"C","title":["Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-9990","authenticated-orcid":false,"given":"Anders","family":"Mellemkj\u00e6r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6385-5108","authenticated-orcid":false,"given":"Mikkel Breinholt","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0023-8564","authenticated-orcid":false,"given":"David","family":"Haldrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-7910","authenticated-orcid":false,"given":"Henning","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8118-4643","authenticated-orcid":false,"given":"Karen Louise","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejim.2023.11.012_bib0001","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejim.2023.11.012_bib0002","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2023.11.012_bib0003","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.ejim.2023.11.012_bib0004","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2023.11.012_bib0005","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.ejim.2023.11.012_bib0006","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S2468-1253(22)00062-0","article-title":"Global multi-stakeholder endorsement of the MAFLD definition","volume":"7","author":"M\u00e9ndez-S\u00e1nchez","year":"2022","journal-title":"The lancet Gastroenterology & hepatology"},{"issue":"1","key":"10.1016\/j.ejim.2023.11.012_bib0007","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.eprac.2022.10.007","article-title":"A meta-analysis on associated risk of mortality in nonalcoholic fatty liver disease","volume":"29","author":"Fu","year":"2023","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.ejim.2023.11.012_bib0008","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/cpf.12526","article-title":"Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease","volume":"39","author":"Rix","year":"2019","journal-title":"Clin Physiol Funct Imaging"},{"issue":"5","key":"10.1016\/j.ejim.2023.11.012_bib0009","doi-asserted-by":"crossref","first-page":"e24557","DOI":"10.1097\/MD.0000000000024557","article-title":"Association of non-alcoholic fatty liver disease and all-cause mortality in hospitalized cardiovascular disease patients: a systematic review and meta-analysis","volume":"100","author":"Saokaew","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.ejim.2023.11.012_bib0010","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/eurjpc\/zwab212","article-title":"Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"29","author":"Alon","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.ejim.2023.11.012_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101643","article-title":"Cardiovascular morbidity and mortality related to non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"48","author":"Bisaccia","year":"2023","journal-title":"Curr Probl Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2023.11.012_bib0012","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1016\/j.dsx.2016.12.033","article-title":"Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis","volume":"11","author":"Mahfood Haddad","year":"2017","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"10.1016\/j.ejim.2023.11.012_bib0013","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2013.07.052","article-title":"A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?","volume":"230","author":"Oni","year":"2013","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.ejim.2023.11.012_bib0014","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1148\/radiol.14140933","article-title":"High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial","volume":"274","author":"Puchner","year":"2015","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.ejim.2023.11.012_bib0015","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eprac.2022.03.016","article-title":"Metabolic associated fatty liver disease increases the risk of systemic complications and mortality. a meta-analysis and systematic review of 12\u2009620\u2009736 individuals","volume":"28","author":"Quek","year":"2022","journal-title":"Endocr Pract"},{"issue":"9","key":"10.1016\/j.ejim.2023.11.012_bib0016","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1097\/MEG.0000000000000909","article-title":"Increased arterial stiffness in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"29","author":"Jaruvongvanich","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.ejim.2023.11.012_bib0017","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/eurheartj\/ehx662","article-title":"Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: mendelian randomization and meta-analysis of 279\u2009013 individuals","volume":"39","author":"Lauridsen","year":"2018","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.ejim.2023.11.012_bib0018","first-page":"419","article-title":"Comprehensive review of cardiovascular disease risk in nonalcoholic fatty liver disease","volume":"9","author":"Josloff","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"issue":"5","key":"10.1016\/j.ejim.2023.11.012_bib0019","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.32519","article-title":"Risk of cardiovascular disease and loss in life expectancy in NAFLD","volume":"76","author":"Shang","year":"2022","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejim.2023.11.012_bib0020","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejim.2023.11.012_bib0021","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijcard.2015.08.107","article-title":"Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders","volume":"201","author":"Lim","year":"2015","journal-title":"Int. J. Cardiol."},{"issue":"8","key":"10.1016\/j.ejim.2023.11.012_bib0022","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review","volume":"73","author":"Stahl","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejim.2023.11.012_bib0023","doi-asserted-by":"crossref","DOI":"10.1007\/s11906-023-01242-8","article-title":"Mechanisms linking Metabolic-Associated Fatty Liver Disease (MAFLD) to cardiovascular disease","author":"Badmus","year":"2023","journal-title":"Curr. Hypertens. Rep."},{"issue":"2","key":"10.1016\/j.ejim.2023.11.012_bib0024","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"Dongiovanni","year":"2015","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.ejim.2023.11.012_bib0025","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/ng.3977","article-title":"Exome-wide association study of plasma lipids in >300,000 individuals","volume":"49","author":"Liu","year":"2017","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.ejim.2023.11.012_bib0026","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jhep.2014.10.010","article-title":"Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2","volume":"62","author":"Zhou","year":"2015","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.ejim.2023.11.012_bib0027","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1007\/s10620-009-1075-y","article-title":"The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk","volume":"55","author":"Alkhouri","year":"2010","journal-title":"Dig. Dis. Sci."},{"issue":"4","key":"10.1016\/j.ejim.2023.11.012_bib0028","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ejim.2023.11.012_bib0029","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ejim.2023.11.012_bib0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.26672","article-title":"Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 Diabetes","volume":"59","author":"Birkenfeld","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ejim.2023.11.012_bib0031","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ejim.2023.11.012_bib0032","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1210\/jc.2015-3476","article-title":"Impaired insulin suppression of VLDL-triglyceride kinetics in nonalcoholic fatty liver disease","volume":"101","author":"Poulsen","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ejim.2023.11.012_bib0033","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00125-005-1682-x","article-title":"Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms","volume":"48","author":"Bugianesi","year":"2005","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.ejim.2023.11.012_bib0034","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00125-003-1111-y","article-title":"Diabetic dyslipidaemia: from basic research to clinical practice","volume":"46","author":"Taskinen","year":"2003","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.ejim.2023.11.012_bib0035","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/hep.26988","article-title":"Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis","volume":"59","author":"Bril","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejim.2023.11.012_bib0036","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1089\/met.2019.0115","article-title":"High-risk atherosclerosis and metabolic phenotype: the roles of ectopic adiposity, atherogenic dyslipidemia, and inflammation","volume":"18","author":"Lechner","year":"2020","journal-title":"Metab Syndr Relat Disord"},{"issue":"9","key":"10.1016\/j.ejim.2023.11.012_bib0037","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"1","key":"10.1016\/j.ejim.2023.11.012_bib0038","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.13973","article-title":"Cardiovascular risk factors in non-alcoholic fatty liver disease","volume":"39","author":"Hagstr\u00f6m","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2023.11.012_bib0039","doi-asserted-by":"crossref","first-page":"l5367","DOI":"10.1136\/bmj.l5367","article-title":"Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults","volume":"367","author":"Alexander","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2023.11.012_bib0040","doi-asserted-by":"crossref","unstructured":"Duell P.B., Welty F.K., Miller M., Chait A., Hammond G., Ahmad Z., et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: a Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;42(6).","DOI":"10.1161\/ATV.0000000000000153"},{"issue":"2","key":"10.1016\/j.ejim.2023.11.012_bib0041","doi-asserted-by":"crossref","first-page":"290","DOI":"10.5009\/gnl210084","article-title":"Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease","volume":"16","author":"Kim","year":"2022","journal-title":"Gut Liver"},{"issue":"1","key":"10.1016\/j.ejim.2023.11.012_bib0042","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000329","article-title":"Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study)","volume":"78","author":"Nabi","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejim.2023.11.012_bib0043","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus","volume":"14","author":"Targher","year":"2018","journal-title":"Nature Reviews Endocrinology"},{"issue":"6","key":"10.1016\/j.ejim.2023.11.012_bib0044","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MEG.0000000000001075","article-title":"Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis","volume":"30","author":"Zhou","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.ejim.2023.11.012_bib0045","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cgh.2011.12.039","article-title":"Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population","volume":"10","author":"Stepanova","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.ejim.2023.11.012_bib0046","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.ejim.2023.11.012_bib0047","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.ejim.2023.11.012_bib0048","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ejim.2023.11.012_bib0049","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejim.2023.11.012_bib0050","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ejim.2023.11.012_bib0051","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1478-3231.2011.02753.x","article-title":"The Framingham risk score and heart disease in nonalcoholic fatty liver disease","volume":"32","author":"Treeprasertsuk","year":"2012","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.ejim.2023.11.012_bib0052","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/hep4.1387","article-title":"Mortality risk detected by atherosclerotic cardiovascular disease score in patients with nonalcoholic fatty liver disease","volume":"3","author":"Golabi","year":"2019","journal-title":"Hepatol Commun"},{"issue":"34","key":"10.1016\/j.ejim.2023.11.012_bib0053","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.11.012_bib0054","doi-asserted-by":"crossref","unstructured":"Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., B\u00e4ck M., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With. Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition). 2022;75(5):429.","DOI":"10.1016\/j.rec.2022.04.003"},{"issue":"6","key":"10.1016\/j.ejim.2023.11.012_bib0055","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","article-title":"Clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"59","year":"2016","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.ejim.2023.11.012_bib0056","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocrine Practice"},{"issue":"25","key":"10.1016\/j.ejim.2023.11.012_bib0057","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejim.2023.11.012_bib0058","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3945\/ajcn.2010.29673","article-title":"Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis","volume":"92","author":"Sofi","year":"2010","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1016\/j.ejim.2023.11.012_bib0059","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0041-1723751","article-title":"Effects of mediterranean diet in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials","volume":"41","author":"Kawaguchi","year":"2021","journal-title":"Semin Liver Dis"},{"issue":"9","key":"10.1016\/j.ejim.2023.11.012_bib0060","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.clnu.2022.06.037","article-title":"The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis","volume":"41","author":"Haigh","year":"2022","journal-title":"Clin Nutr"},{"issue":"5","key":"10.1016\/j.ejim.2023.11.012_bib0061","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.3390\/jcm12051923","article-title":"Types of physical activity in nonalcoholic fatty liver disease and all-cause and cardiovascular mortality","volume":"12","author":"Kim","year":"2023","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.ejim.2023.11.012_bib0062","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.ejim.2023.11.012_bib0063","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"10.1016\/j.ejim.2023.11.012_bib0064","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.11.012_bib0065","unstructured":"NORDISK N. Novo Nordisk A\/S: semaglutide 2.4smg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial Novonordisk.com2023 [cited 2023 28\/08-2023]. Available from: https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=166301."},{"issue":"10019","key":"10.1016\/j.ejim.2023.11.012_bib0066","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.11.012_bib0067","doi-asserted-by":"crossref","unstructured":"Mantovani A., Byrne C.D., Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. The Lancet Gastroenterology & Hepatology. 2022;7(4):367\u201378.","DOI":"10.1016\/S2468-1253(21)00261-2"},{"issue":"7","key":"10.1016\/j.ejim.2023.11.012_bib0068","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"17","key":"10.1016\/j.ejim.2023.11.012_bib0069","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"#cr-split#-10.1016\/j.ejim.2023.11.012_bib0070.1","unstructured":"Medicine N-NLo. Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) (RESOLVE-IT) 2022 [updated 2022-03-23"},{"key":"#cr-split#-10.1016\/j.ejim.2023.11.012_bib0070.2","unstructured":"cited 2023 11\/09-2023]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02704403."},{"issue":"2","key":"10.1016\/j.ejim.2023.11.012_bib0071","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.cgh.2021.03.031","article-title":"Prevalence and factors associated with statin use among patients with nonalcoholic fatty liver disease in the TARGET-NASH study","volume":"20","author":"Thomson","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.ejim.2023.11.012_bib0072","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/hep4.1241","article-title":"Among patients with NAFLD, treatment of dyslipidemia does not reduce cardiovascular mortality","volume":"2","author":"Shahab","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ejim.2023.11.012_bib0073","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ijcard.2018.05.087","article-title":"The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe","volume":"270","author":"Simon","year":"2018","journal-title":"Int J Cardiol"},{"issue":"9756","key":"10.1016\/j.ejim.2023.11.012_bib0074","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.11.012_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.ejim.2023.11.012_bib0076","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12916-022-02288-2","article-title":"Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)","volume":"20","author":"Cho","year":"2022","journal-title":"BMC Med"},{"issue":"10","key":"10.1016\/j.ejim.2023.11.012_bib0077","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.clnu.2022.08.001","article-title":"Statins' efficacy in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"41","author":"Boutari","year":"2022","journal-title":"Clin Nutr"},{"issue":"8","key":"10.1016\/j.ejim.2023.11.012_bib0078","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1210\/jc.2017-00867","article-title":"Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial","volume":"102","author":"Bril","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3 Suppl","key":"10.1016\/j.ejim.2023.11.012_bib0079","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"The national lipid association's statin safety task F. an assessment by the statin liver safety task force: 2014 update","volume":"8","author":"Bays","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.ejim.2023.11.012_bib0080","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 Renewing consensus in portal hypertension","volume":"76","author":"De Franchis","year":"2022","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.ejim.2023.11.012_bib0081","doi-asserted-by":"crossref","first-page":"G724","DOI":"10.1152\/ajpgi.00063.2016","article-title":"Statins improve NASH via inhibition of RhoA and Ras","volume":"311","author":"Schierwagen","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"12","key":"10.1016\/j.ejim.2023.11.012_bib0082","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/82219","article-title":"Statins as a newly recognized type of immunomodulator","volume":"6","author":"Kwak","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.ejim.2023.11.012_bib0083","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fphar.2016.00324","article-title":"Early effects of treatment low-dose atorvastatin on markers of insulin resistance and inflammation in patients with myocardial infarction","volume":"7","author":"Gruzdeva","year":"2016","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.ejim.2023.11.012_bib0084","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins","volume":"64","author":"Marrone","year":"2015","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.ejim.2023.11.012_bib0085","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","article-title":"Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis","volume":"126","author":"Zafra","year":"2004","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ejim.2023.11.012_bib0086","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2023.11.012_bib0087","doi-asserted-by":"crossref","unstructured":"Huang Y.W., Lee C.L., Yang S.S., Fu S.C., Chen Y.Y., Wang T.C.,\u00a0 et al. Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis b patients: a nationwide cohort study. Official journal of the American College of Gastroenterology | ACG. 2016;111(7):976\u201385.","DOI":"10.1038\/ajg.2016.179"},{"issue":"6","key":"10.1016\/j.ejim.2023.11.012_bib0088","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1053\/j.gastro.2019.01.026","article-title":"Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis","volume":"156","author":"Kaplan","year":"2019","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.ejim.2023.11.012_bib0089","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/dom.12922","article-title":"Short- and long-term mortality after bariatric surgery: a systematic review and meta-analysis","volume":"19","author":"Cardoso","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.ejim.2023.11.012_bib0090","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jama.2020.12567","article-title":"Benefits and risks of bariatric surgery in adults: a review","volume":"324","author":"Arterburn","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ejim.2023.11.012_bib0091","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.soard.2020.11.004","article-title":"Safety of metabolic and bariatric surgery in obese patients with liver cirrhosis: a systematic review and meta-analysis","volume":"17","author":"Agarwal","year":"2021","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.ejim.2023.11.012_bib0092","doi-asserted-by":"crossref","DOI":"10.1007\/s11739-023-03417-2","article-title":"Intra-gastric balloon with lifestyle modification: a promising therapeutic option for overweight and obese patients with metabolic dysfunction-associated steatotic liver disease","author":"Van Dijk","year":"2023","journal-title":"Intern Emerg Med"},{"issue":"11","key":"10.1016\/j.ejim.2023.11.012_bib0093","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1136\/gutjnl-2020-323931","article-title":"Alternative treatments for type 2 diabetes and associated metabolic diseases: medical therapy or endoscopic duodenal mucosal remodelling?","volume":"70","author":"ACGv","year":"2021","journal-title":"Gut"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523004090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523004090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T05:26:52Z","timestamp":1712035612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523004090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":94,"alternative-id":["S0953620523004090"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.11.012","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}